A Double-Blind, Randomized, 6-Sequence, 3-Period Crossover Drug-Drug Interaction Study to Evaluate the Pharmacokinetics of WELLBUTRIN SR (Bupropion) and GSK189075 [remogliflozin etabonate] When co-Administered or Administered Alone in Healthy Male Volunteers.

Trial Profile

A Double-Blind, Randomized, 6-Sequence, 3-Period Crossover Drug-Drug Interaction Study to Evaluate the Pharmacokinetics of WELLBUTRIN SR (Bupropion) and GSK189075 [remogliflozin etabonate] When co-Administered or Administered Alone in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Bupropion (Primary) ; Remogliflozin etabonate (Primary)
  • Indications Depressive disorders; Obesity; Seasonal affective disorder; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top